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Abstract
Rapid advance in oncology leads to increasing survival of oncologic patients. More and more of them live long enough to reach either
the natural age ofmenopause or, as a side effect of their oncotherapy, experience the cessation of gonadal function, leading to premature
ovarian insufficiency, with disturbing vasomotor symtoms and long-term negative cardiovascular and skeletal effects. Thus, an ever
increasing number of cancer survivors search endocrinologic help in the form of hormone replacement therapy (HRT). The misinter-
pretation of the WHI (Women's Health Initiative) Study has lead to an irrational fear of female hormone replacement, both by the
general population and medical professionals. It has seemed the logical and safe conclusion to many physicians to avoid HRT,
supposing that this attitude definitely causes no harm, whereas the decision of prescribing estrogen alone or with progestins might
bear oncologic and thromboembolic risks andmay even lead to litigation in case of a potentially related complication. However, it was
known even before the WHI results that premature menopause and hypogonadism decreases the life expectancy of women by years
through its skeletal and cardiovascular effects, and this negative effect correlates with the length of the hypoestrogenaemic period.
Therefore, the denial of HRT also needs to be supported by evidence and should be weighed againts the risks of HRT. Yet, the
oncologic risk of HRT is extremely difficult to assess. In this work we review the latest evidence from in vitro experiments to clinical
studies, regarding HRT in survivors of gynecologic and non-gynecologic cancers. Based on our literature research, we group tumours
regarding the oncologic risk of properly chosen female hormone replacement therapy in cancer survivors as follows: ’HRT is
advanageous’ (e.g. endometrial cancer type I, cervical adenocarcinoma, haematologic malignancies, local cutaneous malignant mel-
anoma, colorectal cancer, hepatocellular cancer); ’HRT is neutral’ (e.g. BRCA 1/2mutation carriers without cancer, endometrial cancer
type II, uterinal carcinosarcoma and adenosarcoma, certain types of ovarian cancer, cervical, vaginal and vulvar squamous cell
carcinoma, prolactinoma, kidney cancer, pancreatic cancer, thyroid cancer); ’HRT is relatively contraindicated’ for various reasons
(e.g. leiomyosarcoma, certain types of ovarian tumours, brain tumours, advanced metastatic malignant melanoma, lung cancer, gastric
cancer, bladder cancer); ’HRT is diasadvantageous and thus contraindicated’ (e.g. breast cancer, endometrial stroma sarcoma, menin-
gioma, glioma, hormone receptor positive gastric and bladder cancer).
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Introduction
Hormone replacement therapy (HRT; also known asmenopausal
hormone therapy, MHT) means substituting estrogen (or
compounds exerting estrogenic effects) and progesterone (or
compounds exerting progestagenic effects) after the cessation
of cyclic ovarian hormone production. In the context of young
oncologic patients with premature ovarian insufficiency (POI)
the term HRT seems to be more appropriate then MHT.
Oncologic risk of MHT requires consideration from two aspects:
the potential of MHT to induce tumours in patients who have no
oncologic history; and the potential to cause cancer recurrence
and progression in cancer survivors. The former question is fre-
quently asked by patients and needs to be explained to those who
receive MHT. To date, a lot of data from large randomised
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controlled trials and relevant guidelines are available in context
of the most common malignancies, such as breast or colorectal
cancer. Most of these are reviewed in the clinical guidelines of
menopausal hormone therapy, such as that of the International
Menopause Society, IMS [1], the National Institute for Health
and Care Excellence, NICE [2] or the American College of
Obstetricians and Gynecologists, ACOG [3].
The situation is far more complex when it comes to cancer
survivors. They can experience premature ovarian insufficiency
as a consequence of cancer treatment (surgery, chemotherapy or
radiotherapy), or as a result of an independent disease (see all the
possible causes of POI, e.g. genetic or autoimmune diseases, or
the consequence of other benign ovarian pathology), or simply
may survive long enough to reach the age of physiological men-
opause around the age of 50. HRT may be necessary because of
menopausal symptoms, but young asymptomatic patients should
also receive hormone replacement if not contraindicated. It is
well known that refusal of MHT decreases not only the quality
of life, but also the life expectancy of youngmenopausal patients
by several years. In a Dutch study, this was found to be 2 years
lost over a 17-year follow-up period, mainly due to cardiovascu-
lar and osteoporotic morbidity [4]. Thus, not only inadequate
initiation of MHT, but also its unsubstantiated denial, ’just to
be on the safe side’, harms the patient.
Professional decision-making, however, is hindered by
several factors. The major problem is the nearly infinite num-
ber of possibilities that biologically characterize the two po-
tentially counteracting participants: the malignant disease and
hormone therapy. Our decision depends on
& the general oncologic characteristics of the malignant
disease and its former or current therapy (the organ affect-
ed, histologic type, molecular oncologic characteristics,
grade and stage of tumour, therapy applied, stage of re-
mission, time of survival since therapy);
& the specifications of the planned hormone substitution
therapy (estrogenic and progestagenic compound type,
dose, sequential or continuous fixed combination regi-
men, route of administration, duration of MHT);
& and the oncologically relevant endocrine caracteristics of
the tumour, e.g. hormone receptor status (presence of hor-
mone receptors, receptor subtypes, receptor splice vari-
ants, or estrogen-related receptors), former or current en-
docrine oncotherapy (aromatase inhibitors, selective estro-
gen receptor modulators, selective estrogen receptor de-
grader, GnRH analogues) or the effect of female hormones
on the given tissue in general, or on the specific tumour
type in particular. It is even possible, that in vivo HRT
exerts its effect on tumour recurrence and progression
(even contradicting in vitro results on isolated cells or
tumour tissues) not by affecting the malignant cells them-
selves, but rather influencing for example the surrounding
stromal tissue, the immune response of the body, or cells
and structures participating in metastatization.
It is obvious from this list that although ’individualized
decision-making’ is needed, data on which this should be
based can not always be readily available. When trying to find
relevant data, depending on the prevalence of the tumour type,
papers from preclinical research, case reports, retrospective
studies, randomized controlled trials and meta-analyses can
be found. Their strength to predict the risks and benefits of
MHT in the given clinical setting is varied, yet, these may be
the only source of information for the clinician.
In this review we try to summarize the data regarding the
advantages and disadvantages of HRT in the most common
tumour types.
Determinants of Estrogen Effect on Tissues
The effect of estrogen on a tissue or a certain cellular function
is not at all straightforward. Classic nuclear estrogen receptors
(ERs), ERα and ERβ exert their effect after estrogen binding
and dimerization via binding to estrogen response elements
(ERE) in the promoter and regulatory regions of their target
genes [Fig. 1]. This binding can be direct or can be mediated
by transcription factors (TFs). Also, ligand (estrogen) inde-
pendent activat ion and ERE-binding of ERs via
phosphorilation triggered by for example growth factor recep-
tors (e.g. HER2, IGF-1R), as well as ER independent
activation and ERE-binding of TFs is known. This activation
can be mediated by endoplasmic reticulum or surface mem-
brane bound classic or G-protein-coupled 7-transmembrane
spanning (GPER or GPR30, xER types) receptors, or estrogen
independent protein kinase activation. [5, 6]
Estrogen sensitivity and ERE mediated activation of cells or
genes can be defined in several ways. When gene upregulation
following the addition of estrogen is measured, over 1000 estro-
gen sensitive genes can be identified, the exact number depend-
ing on cell and tissue type [7]. The other approach is identifying
EREs in the promoter region of genes. ERE databases of the
human genome are available online [8, 9], and include for exam-
ple the following genes: EBAG9, c-fos, OXT, F12, TFF1, LTF,
CTSD, PFDN2, TGF-α, AGT, GREB1, KIAA1243, NRIP1,
MADH9, NME3, TPD52L, and ABCG2. [9].
To make the situation even more complex, estrogen-related
receptors (ERRα, ERRβ, ERRγ), several estrogen-binding
and non-estrogen-binding splice variants (isoforms) of ERα
(e.g. ERα-46, ERα-36) and ERβ (ERβ1-5), and interaction
of ERα and ERβ via heterodimerization have been known
for several years [10, 11]. Taken all these into consideration, it
is clear that the presence of estrogen and its receptor is not
enough to predict the effect of estrogen in any cell type. Yet,
the estrogen (and progesterone) receptor status has long been
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known to be an important prognostic factor and has been used
to determine the mode of oncotherapy in certain cancer types,
for example breast cancer. Estrogen receptor overexpression,
however, has not only been found in the well-known estrogen
dependent tumour types, such as breast, endometrial and ovar-
ian cancer. Altered estrogen and / or progesterone receptor ex-
pression has been documented for example in thyroid cancer
[12–15], Hodgkin’s lymphoma [16–18], B-cell malignancies
[19, 20], brain tumours [21–25], prolactinoma [26, 27], mela-
noma [28–31], lung cancer [32, 33], colorectal cancer [34–36],
gastric cancer [37] and liver cancer [38, 39].
Nevertheless, receptor expression pattern is not enough to
predict the effect of estrogen or progesterone on a given tumour
type. In general, ERα can induce estrogen-dependent prolifera-
tion while ERβ can inhibit it, but the overall biologic effect of
estrogenic compounds on different cells, tissues and tumour
types is determined by the complex interplay of ER subtypes,
isoforms, ER-related receptors and heterodimerization, pres-
ence of transcriptional coactivators and corepressors, as well
as estrogen and non-estrogen mediated phosphorilation of all
the above-listed ’players’. As mentioned in the previous sec-
tion, estrogen effect on the stroma, immune response and par-
ticipants of tumourmetastatization alsomodifies the hormonal
effect in vivo. As the effect is therefore practically
impredictable, experience and its proper interpretation in the
preclinical and clinical setting is inevitable.
Determinants of Progesterone Effect
on Tissues
As both the symptoms and the long-term negative effects
of menstrual cycle cessation are attributed mainly to es-
trogen deficiency, HRT needs to substitute estrogen. Yet,
to prevent the oncologic risk of unopposed estrogen stim-
ulation of the endometrium, progestagenic compounds are
also used in patients with an intact uterus. As the
progestagens used do not have a pure progesterone-like
effect (except for micronised progesterone) but can also
act as activators or inhibitors of different potency on other
steroid hormone receptors (androgen, mineralocorticoid
and glucocorticoid), prediction of E+P HRT effect on tis-
sues simply based on receptor expression and signalling is
nearly impossible. Progesterone signalling is not less
complicated than estrogen signalling, and beyond that,
estrogen and progesterone interaction, progesterone effect
on the tumour stroma, immune cells and the events of
metatstatization and the effect on other steroid hormone
receptors combine to finally determine the overall impact
that progesterone-containing HRT exerts on a certain ma-
lignant disease. Detailed discussion of progesterone sig-
nalling exceeds the scope of this review. Nuclear proges-
terone receptor (PR) A and B activation and progesterone
response element (PRE) binding leads to ’classical’
Fig. 1 Modes of action of estrogen receptors. Estrogen receptors can
exert their effects in several ways. 1.Estrogen + nuclear ER, dimerization,
direct DNA binding. 2. Estrogen + nuclear ER + transcription factor,
DNA binding. 3. Phosphorylation of transcription factor through an
estrogen dependent or independent pathway, DNA binding without ER.
4. Phosphorylation of nuclear ER through an estrogen dependent or
independent pathway, DNA binding without estrogen ligand. 5a. Non-
genomic effect of estrogen via GPER endoplasmic reticulum membrane
bound ER, Ca2+ signalling activated. 5b.Non-genomic effect of estrogen
via cell surface membrane bound mERs, Ca2+ signalling and kinases
activated. E2: estrogen, ER: estrogen receptor, mER (mER-X, mERx):
membrane bound estrogen receptor (-X and x), Gq-mER: G-protein
coupled membrane bound estrogen receptor, GPER/GPR30: G-protein
coupled estrogen receptor 1 / G-protein coupled receptor 30, TF: tran-
scription factor, GF: growth factor
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progesterone signalling, but rapid progesterone effects are
also mediated by membrane-bound PRs, cytoplasmic PRs
and receptor-independent signalling via various signal
transduction pathways, called ’non-classical’ progesterone
signalling, as reviewed in detail by Garg and colleagues
[40] and summarized in Fig. 2 [40–42].
Similarly to what was discussed above in detail with
regard to estrogen, progesteron receptor expression pattern
is also not enough to exactly predict the effect of proges-
terone on a given tissue or tumour type. Therefore, each
cancer type and its relation to MHT requires an indepen-
dent search of the literature. Thus, to make the most ad-
vantage of this work, we included in our search the most
common tumour types, whose survivors are therefore the
most probable to show up with the request of HRT.
Childhood and young adult (ages 20 to 39) cancer survi-
vors will present with premature ovarian insufficiency,
whereas survivors of the most common female cancer
types may come for a professional opinion regarding
HRT at or after the natural age of menopause. The most
common cancer types are listed in Table 1, based on the
2015-2016 data of the American Cancer Society.
In this review, we are going to discuss the relation of MHT
and various cancer types according to the following grouping:
1. Breast cancer
2. Gynecologic cancers
3. Other common non-gynecologic cancers
Breast Cancer
One of the most commonly encountered clinical situation in
the field of HRT in oncologic patients is the request of breast
cancer survivors to relieve their menopausal symptoms. Their
menopause can be the result of either chemo- or radiotherapy,
or some type of antiestrogenic endocrine therapy. The general
attitude is straightforward, as also stated in the guideline of the
International Menopause Society: no hormone replacement
therapy should be given to these patients [1]. Rather, non-
hormonal methods, including lifestyle changes, behavioral
therapy, gabapentine, venlafaxine or fluoxetine should be pre-
ferred [44]. Although the observational and case control stud-
ies before 2002 indicated no increased risk of recurrence
[45–48], HABITS (Hormone Replacement Therapy After
Breast Cancer – Is it Safe?), the first large randomized, con-
trolled trial (RCT) of the field changed the attitude and has
dominated professional approach ever since. HABITS was
stopped in 2003 after 2.1 years as the results showed an in-
creased risk of breast cancer recurrence (n=434, recurrence 26
cases in the HRT group vs. 7 cases in the non-HRT group, HR:
3.3) [49]. The other RCT at the time, the Stockholm Trial was
also stopped based on the results of the HABITS trial, al-
though its results showed no increased risk of recurrence, with
a RR of 0.82 when the trial was prematurely stopped (n=379).
However, there were significant differences between the two
trials effecting the lymph node positivity and tamoxifen appli-
cation. Although the original RCT results seemed to be
Fig. 2 Modes of action of progesterone receptors. (1) Classical proges-
terone receptor activation (slower) through the classical nuclear proges-
terone receptors (PR-A/PR-B). (Progesterone + nuclear PRA/PRB, di-
merization, direct DNA binding. ) Non-classical pathways are more com-
plex. Effect of progesterone via cell surface membrane bound mPRs
(PGRMC1,MPRab,GABAa), Ca2+ signalling and PKA/MAPK (2) acti-
vation or PKG/PKC/MAPK (3) activation. (4) Activation of SRC (tyro-
sine kinase) and MAPK cascade. (5) Growth factors (GnRH, neuropep-
tides and PGE2) can be effective through cAMP, cGMP, NO via nuclear
PRs. (6) Dopamin mediated effects via PKA activation [40–42]
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conflicting, and even now no clear-cut conclusion can be
drawn, trials of the last decade, including extended follow-
up studies of HABITS and the Stockholm Trial have seemed
to indicate an increased recurrance risk of breast cancer after
different HRT regimens, with the relative risk (RR) of recur-
rence varying between 2.0 to 3.6 [50, 51]. In the extended
follow-up of HABITS, Holmberg and colleagues found a
RR of recurrence of 2.4 (n=442, mean HRT duration 24
months, follow-up 5 years, recurrence 22.2% HRT user vs.
8.0% non-user) [52]. The 10-year follow-up results of the
Stockholm Trial also indicate an increased breast cancer re-
currence risk. In the study of Fahlen and coworkers, a hazard
ratio (HR) of 3.6 was detected for recurrence of the disease
(n=378, meanHRT duration 26months, recurrenceHRTusers
7,4% vs. non-users 2.1%) [53].
Not only estrogen + progestagen oral HRT regimens have
been tested, but also tibolone, a compound that is metabolized
to an estrogenic, progestagenic and androgenic isomer and is
routinely used for MHT. The LIFT (Long-Term Intervention
on Fractures with Tibolone) study proved that not only does
tibolone decrease fracture risk in an osteoporotic postmeno-
pausal population, but it also reduces invasive breast cancer
risk significantly (odds ratio 0.32) [54]. The LIBERATE
(Livial Intervention Following Breast Cancer: Efficacy,
Recurrence and Tolerability Endpoints) Trial was conducted
to assess the use of tibolone in breast cancer survivors.
Although bone mineral density (BMD) and climacteric
symptoms significantly improved, the trial was premature-
ly terminated because of the increased recurrence risk of
breast cancer (n=3098, follow-up 3.1 years, breast cancer
recurrence 15.2% with tibolone vs. 10.7% with placebo,
HR: 1.4) [55–57]. Interestingly, cancer recurrence was
only observed in the normal BMD group, suggesting a
local estrogen effect unrelated to the circulating estrogen
in the plasma. Unfortunately, due to the disapointing out-
come of these prematurely halted trials, we could not get a
clear vision on the safety of HRT in breast cancer survi-
vors in the following decade.
Although HRT is generally contraindicated in breast cancer
survivors, mainly based on the studies mentioned above, some
points are worth consideration during decision-making.
1. Different molecules used for HRT and different regimens
resulted in conflicting outcomes regarding cancer recur-
rence risk.
2. The effect of tibolone can be modified by the presence of
ER and parallel endocrine oncotherapy: whereas recur-
rence risk was high when aromatase inhibitor (HR: 2.42)
or GnRH analogue (HR: 2.29) was also used, no signifi-
cant relative risk elevation was seen in ER negative (HR:
1.15) and SERM (tamoxifen) -treated (HR: 1.25) cases.
Differences can be explained by the different
antiestrogenic effects, resulting in up- or downregulation
or blockage of ERs.
3. To relieve the symptoms of urogenital atrophy, local es-
trogen therapy is also commonly used. When used vagi-
nally, a low-dose estrogen tablet delivers an annual
amount of 1,14 mg estrogen, compared to the 182.5 mg
delivered by the standard dose oral estrogen tablet [58].
Comparing vaginal estrogen user breast cancer survivors
and non HRT user breast cancer survivors, Durna and
colleagues found 9.1% recurrence in vaginal estrogen
users versus 29.5% in non-HRT users (RR: 0.18; 0.04-
0.75) [59]. Fahlen and colleagues compared the use of
oral and local estrogen HRT in breast cancer survivors.
Recurrence was detected in 7.4 % vs. 2.1 % of the two
groups, respectively [60]. Mortality between the two
groups, however, was not significantly different. It is gen-
erally accepted, that any form of local estrogen applica-
tion is contraindicated during adjuvant aromatase inhibi-
tor therapy, since the serum estrogen level has to be kept
strictly at zero.
4. The duration of HRT seems also to be of significance,
although direct conclusions can not be drawn here either.
Studies covering longer periods of MHT after breast can-
cer (24-42 months) tend to report more recurrences and
Table 1 The most common
cancer types in childhood, young
adults and females. American
Cancer Society, 2015-2016 [43]
Childhood cancer Young adult cancer Female cancer (new cases)
Leukemia Breast cancer Breast cancer
Brain and spinal cord tumours Lymphoma
(Hodgkin / non-Hodgkin)
Lung cancer
Neuroblastoma Melanoma Colorectal cancer
Wilms tumour Sarcoma Uterine corpus
Lymphoma (Hodgkin / non-Hodgkin) Female genital tract cancers Thyroid cancer
Rhabdomyosarcoma Thyroid cancer Non-Hodgkin lymphoma
Retinoblastoma Testicular cancer Melanoma
Bone cancer (osteosarcoma, Ewing sarcoma) Colorectal cancer Leukemia
Leukemia Pancreatic cancer
Brain and spinal cord tumours Kidney cancer
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increased mortality [52, 60, 61], as compared to shorter
periods of HRT (12-22 months) [59, 62].
5. A special situation arises in BRCA mutation positive
women, following prophilactic bilateral salpingo-
oophorectomy and thus becoming menopausal. In such
situations, the clinician can face the following possibili-
ties and can give the following suggestions according to
Finch and colleagues [63]:
& If breasts are intact and there is no history of breast
cancer: in both BRCA1 and BRCA2 mutants, MHT
can be offered to the age of natural menopause (50
years of age).
& If prophylactic mastectomy has been performed but
there is no history of breast cancer, MHT should be
offered to the age of natural menopause.
& If the patient had breast cancer,MHT is contraindicated.
& In a recent international cohort study of BRCA-1 mu-
tation women after prophylactic oophorectomy and
with intact breast, the risk of breast cancer was found
elevated when estrogen-progestin HRT was
applicated, but the risk did not increase with
estrogen-only therapy. This finding is in accordance
with the observations with MHT and breast cancer
risk in the natural menopause, and raise the indication
of removing the uterus also at prophylactic oophorec-
tomy in BRCA mutation women. [64]
Gynecologic Cancers
Ovarian Cancer
Although ovarian tumours can be histologically very various
and thus general guidelines are almost impossible to make as
far asMHT is concerned, the situation is a little more simple in
clinical practice, since approximately 90% of ovarian malig-
nancies are epithelial ovarian tumours. Several studies and
their meta-analyses have shown that MHT either does not
increase recurrence of the malignant disease or (in some stud-
ies, e.g. Mascharenas et al.) it even increases the ovarall sur-
vival of patients significantly. [65–72]
The follow-up periods of the studies cited vary between 42
months to 19 years, thus these results are true in the long run.
The use of MHT in more rare types of ovarian tumours
have less strong evidence, given the smaller number of cases
and thus the difficulty of collecting population based data.
Usually it is stated that HRT after the treatment of germ cell
tumours probably carries no additional recurrence risk [73].
Endometrioid ovarian cancer is usually mentioned as a type
that might be sensitive to estrogen a thus avoidance of HRT is
often suggested. [73, 74]
This, however, might seem to be illogical, considering the
fact that endometrial adenocarcinoma survivors are candidates
for HRT, as shown in the following section.
Another type of ovarian cancer where the general sugges-
tion is to avoid HRT is granulosa cell tumour, the most com-
mon sex-chord stromal ovarian tumour. Although there is no
direct evidence to prove or disprove the long-term negative
effect of HRTon granulosa cell tumour survivors, considering
the hormonally – endocrinologically active character of these
tumours, it may be safer not to initiate HRT in these patients.
[73, 75, 76]
Endometrial Cancer
Endometrial cancer is estrogen sensitive in 90% of the cases
(type I) and estrogen independent in only 10% (type II, most
commonly serous papillary carcinoma). Although one could
expect an increased recurrence rate after the initiation of hor-
mone replacement therapy, the studies published over the past
decades do not support this hypothesis. Several small obser-
vational studies have found consistently that recurrence rate
and disease free survival were not worse, furthermore, in most
cases they were found to be even better in HRT groups than
non-HRT groups [77–81]. The studies were far not uniform:
in most cases, stage I and II (in one study, III as well) patients
were included. Follow-up times were 42-87 months, and HRT
was either estrogen only or combined estrogen + progestagen.
Similar results were found by both the only prospective
randomized controlled trial of the field involving over
1200 patients [82] and a meta-analysis of nearly 900
HRT patients vs. 1100 controls [83]. The latter meta-
analysis also shoved that estrogen+progestin HRT had a
protective effect against cancer recurrence (OR: 0.23;
95% CI 0.08-0.66), whereas estrogen-only therapy did
not show this effect (OR: 0.35; 95% CI 0.06-2.10).
As to when to start HRT, we can only refer to the studies
listed above. HRTwas initiated after between 1 to 60 months
of disease free survival (after surgery), but in most cases the
period that passed after surgery was between 3-12 months.
No specific studies can be found on HRT in survivors of
estrogen-independent, agressive type II endometrial cancers,
but as they are not sensitive to estrogen, it is logical to think
that HRT use is not more dangerous in this disease than in the
hormone sensitive histologic forms of endometrial cancer.
Uterine Sarcoma
Uterine sarcomas include leiomyosarcomas, carcinosarcomas,
adenosarcomas and endometrial stroma sarcomas.
Endometrial stroma sarcomas overexpress estrogen and
progesteron receptors and estrogen HRT and tamoxifen were
reported to have an adverse effect on the disease outcome
[84]. HRT in these tumours should therefore be avoided.
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Although leiomyosarcomas very often overexpress estro-
gen and progesteron receptors [85], removal of the ovaries
during hysterectomy did not improve the 5-year overall sur-
vival in the study published byKapp and colleagues [86]. This
may indicate, that leiomyosarcoma is not hormone sensitive
and HRT may be given, as suggested by some authors [87].
Others, however, consider HRT too risky for these patients
and vote against, given the lack of direct data to support or
refute its safety [75].
In carcinosarcomas and adenosarcomas, HRT can be
used [87].
Cervical Cancer
80-90% of cervical cancer is squamous cell carcinoma, which
is known not to be estrogen dependent. As Ploch demonstrat-
ed decades ago [88], HRT in either estrogen-only or a com-
bined E+P formwas advantageous for the patients. In the HRT
group, recurrence was 20% and 5-year overall survival 80%,
whereas in the control group these were found to be 32% and
65%, respectively.
10-20% of cervical cancer is cervical adenocarcinoma
and its biological behaviour resembles endometrial can-
cer. This needs to be taken into consideration when mak-
ing decision of HRT and probably it is beneficial to chose
a combined E+P regime, as discussed above in the section
about endometrial cancer. Undoubtedly, at least to our
present knowledge, treated cervical cancer is not a contra-
indication for HRT.
Vaginal and Vulvar Cancer
Most vaginal and vulvar cancers are squamous cell carcino-
mas, and behave similarly to squamous cell cervical cancer, as
far as hormone insensitivity is concerned [89, 90]. Thus,MHT
is not contraindicated.
Vaginal (clear-cell) adenocarcinoma most commonly
developes after in utero diethylstilbestrol exposition, and vul-
var adenocarcinoma can develop from Bartholin’s glands.
These forms of adenocarcinoma are too rare and their relation
to HRT is not well determined, therefore no clear guidance can
be given. Some sporadic case reposts can be found in the
literature implying a connection between unopposed estrogen




Malignant haematologic diseases include for example acute
and chronic lymphoid and myeloid leukaemia, Hodgkin
lymphoma, non-Hodgkin lymphoma and myeloma multiplex.
The treatment of haematologic malignancies can cause pre-
mature ovarian insufficiency via both chemotherapy and stem
cell transplantation. The beneficial effect of estrogen on
haemopoietic cells has been showed in several ways.
Lymphocyte precursors are regulated by sex steroids [92];
myeloid leukaemia cells express estrogen receptors [93] and
their methylation is related to patient survival [94]; pregnancy
is protective against the development of Hodgkin
lymphoma[95]; former HRT decreases the risk of B-cell
non-Hodgkin lymphomas in postmenopausal women[96];
estrogen influences the proliferation, differentiation and
survival of B-linage precursors [97] and by decreasing
local IL-6 production, improves the disease-free and
overall survival in diffuse large-cell lymphomas [98,
99]. The studies that directly address the question of MHT
after oncotherapy of malignant haematologic diseases found
no increase in the recurrence of the disease or excessmortality,
while significant alleviation of menopausal symptoms was
demonstrated [100]. In summary, at least neutral effect of
HRT on malignant haematologic diseases can be demonstrat-
ed, but most probably estrogen supplementation even exerts a
positive effect on these diseases [101].
Brain Tumours
Even in the past years, conflicting data can be found about the
effect of HRTon the incidence of brain tumours in general and
meningioma and glioma in particular. It, however, seems
clear, that estrogen and progesterone can promote the growth
of malignant brain tumours. It has been observed that menin-
giomas are more common in women, and grow faster in the
luteal phase of the cycle and during pregnancy [102, 103],
indicating the role of progesterone effect. 58-83% of menin-
giomas express progesterone receptor as opposed to 0-8 %
expressing estrogen receptor [104, 105]. Inconsistent results
of studies indicate various relationship between the different
forms of HRT and brain tumours: MHT increases the risk of
meningioma by 30-80 %, but not that of glioma [106]; menin-
giomas can grow as a result of progesterone, estrogen and
androgen stimulus [107]; estrogen-only HRT, but not E+P
HRT increased the risk of brain tumours, glioma and menin-
gioma in a large UK database of women aged 50-79 [108];
HRT but not oral contraceptive use was associated with an
increased meningioma risk [109]; progesterone-only contra-
ception is associated with a shorter progression-free survival
i n p r emenopau s a l women w i t h WHO Grade I
meningioma [110]. Taken all these together, it seems to be
clear that brain tumours, and especially meningioma and gli-
oma, may be sensitive to estrogen and even more to proges-
terone, and hormones can stimulate their growth and recur-
rence, therefore HRT should be avoided in these patients.
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Prolactinoma
Due to its well-established estrogen sensitivity, and the fre-
quency of the clinical situation of requirement of HRT in
prolactinoma patients, prolactin producing pituitary adenomas
are discussed in a separate section. Traditionally,
prolactinomas were considered a contraindication for estro-
genic treatment including combined contraceptive pills and
hormone replacement therapy. It is known, that clinically sig-
nificant tumour growth is very rare (1-2%) during pregnancy
and during low-dose (<30 ug) ethynil estradiol containing
contraceptives in case of a microprolactinoma, whereas
macroadenomas grow much more frequently in an estrogenic
milieu, e.g. their 30-40% grow during pregnancy. The pres-
ence or history of a microprolactinoma should therefore not be
considered a contraindication for HRT in the case of
hypogonadism or in the presence of menopausal symptoms
[111]. In case of a macroprolactinoma, thorough case-by-case
evaluation is required, and if estrogen therapy is prescribed,
and very close monitoring of the prolactinoma size and activ-
ity is necessary, also keeping in mind that the sequential form
of HRT (or cyclic oral contraceptive use) masks the important
symptom of ovulatory dysfunction and menstrual irregulari-
ties [111]. In contrast, it has not been proven that even higher
doses of estrogen (a cumulative 19 mg/kg body weight) used
in normoprolactinaemic patients for prolonged periods (5-15
years) would cause hyperprolactinaemia [112].
Malignant Melanoma
Malignant melanoma is one of the most aggressive tumours.
Its different biological behaviour in males and females is well
known: men tend to have more rapid progression and earlier
metastases, leading to increased mortality and decreased sur-
vival. The response of melanoma cells to female hormones,
however, has been reported controversial. Some studies report
protective effects of estrogen [113, 114], others found
estrogen-only HRT increasing the risk of skin malignant mel-
anoma, which was not the case for E+P combined HRT [115].
The contradiction can be solved if we consider the signifi-
cance of estrogen receptor-β (ERβ) in malignant melanoma.
While ERα is associated with a proliferative and tumour pro-
moting effect, ERβ has an antitumour effect, through the in-
hibition of the PI3K/Akt pathway [116]. ERβ expression
leads to a better prognosis, while decreased expression of
the receptor results in poorer prognosis and the metastatic state
of the disease [117–120]. This knowledge may lead to the use
of ERβ expression determination of the tumour and the use of
estrogen or ERβ agonists in the treatment of melanoma.
Considering MHT, local, and thus probably ERβ-rich tu-
mours should be handled differently from advanced, metasta-
tic cases. In the former group, estrogen supplementation might
even be advantageous, but at least will not have adverse
effects, as demonstrated by a study of 206 patients suffering
from stage 1 or 2 cutaneous melanoma and followed up for 5
years after surgery [121]. One out of the 83 HRT-receivers
died of melanoma, whereas 22 of the 123 patients in the
non-HRT group died of the disease by the end of the 5 years.
The safety of MHT in advanced, metastatic melanoma
malignum is unclear and no recommendation can be made
regarding its use.
Lung Cancer
Lung cancer in the past decades has also become one of the
tumours considerded to be estrogen-dependent. Although
ERβ generally starts anti-tumour signalling, in non-small cell
lung cancer it has been established as a tumour promoter, most
probably via interactions with receptor splice variants, EGFR
receptor signalling and G-protein coupled estrogen receptors
[122]. Several in vitro and in vivo studies have demonstrated
the tumour promoting effect of estrogen in lung cancer, and
the prognostic value of ERα and ERβ expression [122, 123].
Clinical studies have come to conflicting conclusions, al-
though different settings make comparison difficult.
Nevertheless, neutral [124], positive [125] and negative
[126] correlation between lung cancer incidence and mor-
tality have also been reported. Given that the direction of
research is now the application of antiestrogenic agents
and aromatase inhibitors in the treatment of lung cancer
[127], it is logical that estrogen as part of MHT should not
be used in lung cancer patients.
Colorectal Cancer
Colorectal cancer presents in less severe forms in women than
in men, indicating a protective effect of female hormones
[128–130]. Indeed, studies of the field unanimously indicate
that estrogen decreases the incidence of colorectal cancer and
decreases the progression of the disease [131–136]. This is
due to the presence of the ERβ exerting anti-tumour effect
[137]. The latest research indicate that ERβ expression can
even be used as a positive prognostic marker in the treatment
of colorectal cancer [138–140]. In the light of these results,
there is no doubt that MHT has a positive effect on colorectal
cancer and survivors of the disease suffering from the symp-
toms of ovarian insufficiency should be offered MHT.
Kidney Cancer
Several studies have concluded that no relation between MHT
and kidney cancer can be established [141–145], therefore
survivors of kidney cancer can be offered HRT if indicated.
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Gastric Cancer
ER positivity has long been known to be associated with poor
outcome of gastric cancer treatment: ER+ cases are generally
more disseminated and less differentiated [146]. Postperative
survival rates are significantly worse in ER+ vs. ER- cases (15
% vs. 62%) as well as in progesterone receptor positive cases
[147]. In the past years, ERα and ERβ isoforms have been
identified as prognostic markers of gastric cancer [148]. For
example, ERα66 has been reported in poorly differentiated
gastric cancer, ERα36 is found more often in lymph node
metastases, and ERβ1 is associated with low grade tumours
[148]. Besides ERα, androgen receptor expression was also
found to be associated with a poor prognosis and decreased
progress free survival [149]. Beyond the hormone receptors
and in the lack of clinical trials, two further – and contradicting
– clinical research papers are worth consideration. Kim and
colleagues reported that the clinical outcome and the overall
survival was much poorer among female gasctric cancer pa-
tients than among males [150]. Brusselaers and colleagues,
however, found a decreased esophageal and gastric adenocar-
cinoma incidence among ever-users of estrogen-only and E+P
combined HRT, too, as compared to non-users of HRT, in a
Swedish population of approximately 1.150.000 [151].
Taking all these data into consideration, starting MHT to gas-
tric cancer survivors should rather be avoided, and especially
so in case of estrogen or progesterone receptor positive
tumours.
Liver Cancer
It has been almost 30 years since Adami and colleagues re-
ported a decreased risk of hepatocellular cancer following
MHT [152]. The role of estrogen can be a strong antioxidant
and anti-inflammatory effect, thus preventing fibrosis as a key
step towards liver carcinogenesis [153]. Estrogen can also
inhibit the progression of hepatitis B virus infection, thus
inhibiting hepatocellular carcinoma [154]. These effects add
up to a decreased incidence of hepatocellular cancer and better
overall survival among patients that received MHT [155].
Bladder Cancer
Bladder cancer has been known to be more aggressive in
women then in males. 12-18% of bladder cancers are ER
positive, and ER+ tumours tend to be of higher grade than
ER- ones [156]. Former use of MHT was reported to double
the risk of bladder cancer [157]. Both in vitro and in vivo
studies indicate the role of estrogen in the initiation and pro-
gression of bladder cancer [158]. Applying the selective es-
trogen modulator tamoxifen in bladder cancer seems to be
effective, although only initial clinical pilot studies are avail-
able [159, 160]. Combination of antiestrogen + BCG therapies
are also experimented with [161]. In summary, bladder cancer
should be considered an estrogen sensitive tumour, and al-
though no direct clinical evidence is available, MHT should
not be prescribed to survivors of this type of malignancy.
Thyroid Cancer
Thyroid malignancy is more common in women than in men.
Several epidemiologic studies have been carried out, but no
strong evidence of relation between MHT and differentiated
thyroid cancer could be found [162–168]. This is not changed
even by the fact that in the past years, both positive and neg-
ative associations have been reported between the expression
of estrogen and progesteron receptors and the outcome of
thyroid cancer [169, 170]. Thyroid cancer survivors often re-
ceive suppressive doses of thyroxin substitution to maintain
subclinical hyperthyroidism in order to suppress TSH and thus
decrease recurrence risk. Is is known that subclinical hyper-
thyroidism increases the risk of cardiovascular disease and
accelerated bone loss, therefore estrogen substitution, that
counteracts both of these negative effects in the case of men-
opause is even more indicated. Increased frequency of
breast cancer among thyroid cancer survivors has been
reported but mostly it is attributed to the late effect of
radioiodine therapy of the primary malignancy of the thy-
roid, although no definitive consesus has been reached yet
[171]. In summary, former thyroid cancer should not be
considered a contraindication to MHT.
Pancreatic Cancer
Based on 27 case-control and cohort studies, Tang and col-
leagues made a meta-analysis which revealed that the risk of
pancreatic cancer is not associated with exogenous hormone
use (oral contraceptives or MHT) or menstrual factors (age at
menarche, age at menopause, hysterectomy or oophorectomy)
[172]. Pancreatic cancer treatment in the patient’s history does
not contraindicate MHT.
Conclusions
As a result of rapid advance in oncology, both the diagnosis
and the treatment of malignant tumours has been constantly
improving, leading to the increasing survival of oncologic
patients. More and more of them live long enough to reach
either the natural age of menopause or, as a side effect of their
oncotherapy, experience the cessation of their gonadal func-
tion, leading to premature ovarian insufficiency. Thus, an ever
increasing number of cancer survivors search endocrinologic
help in the form of the replacement of their missing female
hormones. Often it is not the endocrinologist who is first asked
by the patient, but other members of the professional staff
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involved in her oncologic care, including the oncologist, gy-
necologist, general practitioner, or even the radiologist or the
oncologic nurse. The general attitude has been defensive: ig-
norance of the latest results in the field of menopausal hor-
mone therapy and false concepts dating back to the WHI
(Women’s Health Initiative) Study results almost two decades
ago [173]. The misinterpretation of the results of this study are
well known among the specialists of the field of menopausal
medicine and will not be discussed here. The net outcome,
however, became an irrational fear of female hormone re-
placement, both by the general population and medical pro-
fessionals. It might has seemed the logical and safe conclusion
to many physicians that it is better to avoid HRT, because this
attitude definitely causes no harm, whereas the decision of
prescribing estrogen with or without progestins for a patient
might bear oncologic and cardiovascular risks, may lead to
litigation in case of a potentially related complication, and
requires meticulous and continuous self-education in the field
not to miss the latest evidence. The major mistake in this
reasoning is the baseline theory of not harming by avoiding
HRT. It was known even before the WHI results that prema-
ture menopause and hypogonadism decreases the life expec-
tancy of women by years through its skeletal and cardiovas-
cular effects, and this negative effect correlates with the length
of the hypoestrogenaemic period. 17 years of untreated
hypogonadism add up to losing 2 life-years [4], and every year
of delay of menopause decreases cardiovascular mortality risk
by 2% [174]. The quality of a life lived with severe menopaus-
al symptoms is yet another matter not to forget. Therefore, it is
not prescribing HRT for a young patient suffering from pre-
mature ovarian insufficiency (POI) that requires professional
explanation - as it is clearly stated also by the latest guidelines
of the International Menopause Society [1] and the Global
Consensus Statement on MHT [175]. It is the denial of HRT,
a decision proved to harm the patients health and decrease her
life expectancy, that needs to be supported by evidence and
should be weighed againts the risks (oncologic or other) of
HRT. Denying HRT ’just to be on the safe side’ is unaccept-
able – we can only make this maleficent decision if the defin-
itive harm caused to our patient by it is smaller than the
suspected harm of HRT.
Yet, it is not easy to assess the HRT-related extra risks of
HRT in cancer survivors. Practically, every tumour is a new and
potentially unprecedented entity, as far as its oncogenic muta-
tions, hormone receptor status and biological beviour are con-
cerned, even if medical science tries to group tumours accord-
ing to organ, histology or molecular characteristics. The vari-
ability of the stage, grade and former oncotherapy received by
Table 2 Categories of cancer types according to oncologic risk (recurrence, progression) of hormone replacement therapy
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the patient complicates decesion making even further. It is clear
that deciding for or against HRT should always be individual-
ized and decision should be made together with the patient. The
risk-benefit assessment can be based on a wide range of scien-
tific evidence of different quality, depending on their availabil-
ity: from in vitro studies to clinical investigations, and the latter
ranging from individual case reports to meta-analysis of several
randomized prospective trials, and even indirect evidence (e.g.
epidemiologic data of tumour behaviour in the different sexes,
during hormonally altered periods like in pregnancy, or HRT
effect on tumours not in cancer survivors etc.). In this reviewwe
have tried to collect data about the most common types of
tumours, in an attempt to help clinical decisions (Table 2).
Based on the evidence gathered so far, adequately chosen fe-
male hormone substitution can be clearly advantageous in some
cancers (e.g. endometrial cancer, haematologic malignancies or
colorectal carcinoma) and harmful in hormone dependent
others (e.g. breast cancer, meningioma or ER+/PR+ gastric
cancer). In certain tumours or in their subgroups, the risk of
HRT seems to outweigh the potential benefits and thorough
individualized decision-making is necessary (e.g. lung cancer
or bladder cancer), whereas in many tumour types MHT is
neutral for the malignant disease and thus it should not be
denied (e.g. cervical cancer, kidney tumours or pancreatic can-
cer). In many situations, however, when more rare cancer types
are faced, individual search of the literature for the specific
tumour will be necessary. Clinical evidence of recurrence risk
of the given cancer type, weighed against the negative long-
term effects of avoiding HRT, the general state and life-
expectancy of the patient, the severity of her hypoestrogenic
and other symptoms, and her subjective fear of the recurrence
of the disease, which is understandably always dominant in
cancer survivors, will help to find the best solution.
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